An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of rebamipide by once daily
intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with
active ulcerative colitis, who are being treated with oral aminosalicylic acid (ASA).